EXHIBIT Study

The effects of exercise in patients with melanoma undergoing immune checkpoint inhibitor (ICI) immunotherapy

Participate in the EXHIBIT study

Treatment-related side effects and toxicities can occur in more than 90% of patients receiving ICI immunotherapy, impacting their well-being, quality of life, and treatment adherence/completion. Exercise has been demonstrated as a safe and feasible strategy to alleviate treatment-related side effects, such as fatigue, in patients receiving other cancer treatments. However, evidence on the effects of exercise in patients receiving immunotherapy is lacking. The EXHIBIT Study aims to explore the effects of exercise concurrent to ICI immunotherapy, for patients with melanoma, through patient-reported outcomes (such as treatment-related side-effects and quality of life), physical outcomes (such as body composition, strength, and fitness), blood biomarkers (such as immune and inflammatory markers), and other specific outcomes (such as disease progression, treatment completion, and hospital admissions).

All participants will receive:

• A Fitbit watch
• Comprehensive physical assessments
• The chance to receive a free supervised exercise program during the course of ICI immunotherapy

You may be eligible to participate if you:

• Are 18+ years of age
• Have been diagnosed with melanoma
• Are scheduled to receive ICI immunotherapy treatment

If you are interested in participating, please contact the exercise oncology team via email: ExerciseOncology@acu.edu.au or phone: 03 9230 8268

This study has been approved by the ACU Human Research Ethics Committee (2024-3928RC).